Avalo Therapeutics, Inc.·4

Jun 9, 4:24 PM ET

Caissa Capital Management ltd. 4

4 · Avalo Therapeutics, Inc. · Filed Jun 9, 2023

Insider Transaction Report

Form 4
Period: 2023-06-07
Transactions
  • Purchase

    Common Stock

    2023-06-08$3.93/sh+6,398$25,1261,395,597 total(indirect: See Footnote (1))
  • Purchase

    Common Stock

    2023-06-07$3.49/sh+2,984$10,4181,389,199 total(indirect: See Footnote (1))
  • Purchase

    Common Stock

    2023-06-09$4.14/sh+5,044$20,8961,400,641 total(indirect: See Footnote (1))
Holdings
  • Common Stock

    182,300
Footnotes (5)
  • [F1]Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.6, inclusive.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.775 to $4.22, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.01 to $4.3, inclusive.
  • [F5]These shares are directly owned by Mr. Golestaneh in his personal capacity.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT